Glioblastoma : clinical and genetics prognosis factors

Glioblastoma (GBM) is the most malignant and most aggressive brain tumor with a median survival of one year despit progress in diagnosis and therapy. It’s high-grade malignancy, called astrocytoma grade IV. It’s characterized by a rapidly progressive clinical deterioration and molecullares alterations in distincts genetics pathways. The diagnosis is established by nuclear imaging magnetic raisonnance and confirmation is made by pathological study based on the WHO criteria. Therapeutic strategy based on surgery, radiotherapy and chemotherapy. Age and neurological status as assessed by the Karnofski index and mutation of the IDH are the most important factors associated with prognosis. The aim is to highlight the value of molecular analysis in the identification of histopathological subtypes, clinical and genetic factors that predict prognosis.